Comparison of AUA and phoenix definitions of biochemical failure following permanent brachytherapy for prostate cancer.

[1]  G. Merrick,et al.  A biochemical definition of cure after brachytherapy for prostate cancer. , 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  R. Stock,et al.  Long-term biochemical control and cause-specific survival in men with Gleason grade Group 4 and 5 prostate cancer treated with brachytherapy and external beam irradiation. , 2020, Brachytherapy.

[3]  H. G. van der Poel,et al.  Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. , 2019, European urology.

[4]  W. J. Morris,et al.  Using a surgical prostate-specific antigen threshold of >0.2 ng/mL to define biochemical failure for intermediate- and high-risk prostate cancer patients treated with definitive radiation therapy in the ASCENDE-RT randomized control trial. , 2018, Brachytherapy.

[5]  Nicholas G Zaorsky,et al.  What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[6]  P. Shrake,et al.  25-Year disease-free survival rate after irradiation for prostate cancer calculated with the prostate specific antigen definition of recurrence used for radical prostatectomy. , 2012, The Journal of urology.

[7]  Y. Yamada,et al.  Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer. , 2011, Urology.

[8]  R. Stock,et al.  Outcomes for patients with high‐grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy , 2009, BJU international.

[9]  M. Kattan,et al.  Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. , 2009, International journal of radiation oncology, biology, physics.

[10]  A. Partin,et al.  Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion--"nadir + 2"? , 2008, Urology.

[11]  Michael W Kattan,et al.  Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Paul Schellhammer,et al.  Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.

[13]  Barry S Rosenstein,et al.  Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. , 2005, International journal of radiation oncology, biology, physics.

[14]  D. Kuban,et al.  PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. , 2004, International journal of radiation oncology, biology, physics.

[15]  B. Trock,et al.  A critical analysis of the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiation and Oncology criteria. , 2002, The Journal of urology.

[16]  F. Critz.  A standard definition of disease freedom is needed for prostate cancer: undetectable prostate specific antigen compared with the American Society of Therapeutic Radiology and Oncology consensus definition. , 2002, The Journal of urology.

[17]  R. Stock,et al.  Intraoperative dosimetric representation of the real-time ultrasound-guided prostate implant. , 2000, Techniques in urology.

[18]  R. Stock,et al.  A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. , 1995, International journal of radiation oncology, biology, physics.

[19]  I. König,et al.  Comparison of outcome endpoints in intermediate- and high-risk prostate cancer after combined-modality radiotherapy. , 2019, Brachytherapy.

[20]  M. Keyes,et al.  Long‐Term Prostate Specific Antigen Stability and Predictive Factors of Failure after Permanent Seed Prostate Brachytherapy , 2018, The Journal of urology.